Literature DB >> 21312074

Juvenile dermatomyositis.

Michelle Batthish1, Brian M Feldman.   

Abstract

Juvenile dermatomyositis (JDM) is a rare, often chronic autoimmune disease with onset during childhood. It is characterized by weakness in proximal muscles and pathognomonic skin rashes. Although the etiology remains unclear, it has been proposed that JDM is caused by a vasculopathy within the muscle tissue and multiple other organ systems of genetically susceptible individuals, possibly in response to environmental triggers. The goals of treatment include control of the underlying inflammatory myositis and prevention and/or treatment of complications (eg, contractures and calcinosis). Delayed treatment may lead to poorer outcome in terms of disease course and calcinosis. The course in JDM is variable. Monocyclic disease occurs in about one third of patients. These patients have a good response to standard therapy. Early recognition and aggressive immunosuppressive treatment result in improved prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312074     DOI: 10.1007/s11926-011-0167-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  51 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

Authors:  Lauren M Pachman; Rebecca Lipton; Rosalind Ramsey-Goldman; Eli Shamiyeh; Kathy Abbott; Eduardo P Mendez; Alan Dyer; Deborah Mc Curdy; Larry Vogler; Ann Reed; Gail Cawkwell; Lawrence Zemel; Christy Sandborg; Rafael Rivas-Chacon; Christine Hom; Norman Ilowite; Abraham Gedalia; Jonathan Gitlin; Michael Borzy
Journal:  Arthritis Rheum       Date:  2005-04-15

3.  Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting.

Authors:  Eleanor M Pullenayegum; Catherine Lam; Cedric Manlhiot; Brian M Feldman
Journal:  J Clin Epidemiol       Date:  2008-05-16       Impact factor: 6.437

Review 4.  Immunopathogenesis of juvenile dermatomyositis.

Authors:  Sahil Khanna; Ann M Reed
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

Review 5.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

6.  Juvenile dermatomyositis: a clinical and immunologic study.

Authors:  L M Pachman; N Cooke
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

7.  MHC Class I overexpression on muscles in early juvenile dermatomyositis.

Authors:  Charles K C Li; Hemlata Varsani; Janice L Holton; Bin Gao; Patricia Woo; Lucy R Wedderburn
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

8.  Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset.

Authors:  C Manlhiot; L Liang; D Tran; A Bitnun; P N Tyrrell; B M Feldman
Journal:  Rheumatology (Oxford)       Date:  2008-02-27       Impact factor: 7.580

9.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Aneel Gursahaney; Ka-Leung Ngai; Jennifer A Daru; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 10.  Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes.

Authors:  A V Ramanan; Brian M Feldman
Journal:  Rheum Dis Clin North Am       Date:  2002-11       Impact factor: 2.670

View more
  4 in total

1.  Juvenile dermatomyositis: a tertiary center experience.

Authors:  Kenan Barut; Pinar Ozge Avar Aydin; Amra Adrovic; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

2.  Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis.

Authors:  Esther A Habers; Marco van Brussel; Anneli C Langbroek-Amersfoort; Annet van Royen-Kerkhof; Tim Takken
Journal:  BMC Musculoskelet Disord       Date:  2012-06-21       Impact factor: 2.362

3.  Being on the juvenile dermatomyositis rollercoaster: a qualitative study.

Authors:  Polly Livermore; Suzanne Gray; Kathleen Mulligan; Jennifer N Stinson; Lucy R Wedderburn; Faith Gibson
Journal:  Pediatr Rheumatol Online J       Date:  2019-06-18       Impact factor: 3.054

4.  Feasibility of the wingate anaerobic exercise test as a clinical measure in patients with juvenile dermatomyositis.

Authors:  Saunya Dover; Samantha Stephens; Hayyah Clairman; Andrew Abesamis; Omidali Aghababaei Jazi; Stephanie Babij; Jo-Anne Marcuz; Natasha Naraidoo; Jing Pan; Eleanor Pullenayegum; Dax Rumsey; Kristi Whitney; Brian M Feldman
Journal:  Pediatr Rheumatol Online J       Date:  2022-03-28       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.